Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
Identifieur interne : 000043 ( Main/Corpus ); précédent : 000042; suivant : 000044Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
Auteurs : Azita Hajhossein Talasaz ; Hessam Kakavand ; Benjamin Van Tassell ; Maryam Aghakouchakzadeh ; Parham Sadeghipour ; Steven Dunn ; Babak GeraielySource :
- Cardiovascular drugs and therapy [ 1573-7241 ] ; 2020.
Abstract
Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.
DOI: 10.1007/s10557-020-07037-2
PubMed: 32671601
PubMed Central: PMC7360896
Links to Exploration step
pubmed:32671601Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.</title><author><name sortKey="Talasaz, Azita Hajhossein" sort="Talasaz, Azita Hajhossein" uniqKey="Talasaz A" first="Azita Hajhossein" last="Talasaz">Azita Hajhossein Talasaz</name><affiliation><nlm:affiliation>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Kakavand, Hessam" sort="Kakavand, Hessam" uniqKey="Kakavand H" first="Hessam" last="Kakavand">Hessam Kakavand</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Van Tassell, Benjamin" sort="Van Tassell, Benjamin" uniqKey="Van Tassell B" first="Benjamin" last="Van Tassell">Benjamin Van Tassell</name><affiliation><nlm:affiliation>Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aghakouchakzadeh, Maryam" sort="Aghakouchakzadeh, Maryam" uniqKey="Aghakouchakzadeh M" first="Maryam" last="Aghakouchakzadeh">Maryam Aghakouchakzadeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Sadeghipour, Parham" sort="Sadeghipour, Parham" uniqKey="Sadeghipour P" first="Parham" last="Sadeghipour">Parham Sadeghipour</name><affiliation><nlm:affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Dunn, Steven" sort="Dunn, Steven" uniqKey="Dunn S" first="Steven" last="Dunn">Steven Dunn</name><affiliation><nlm:affiliation>University of Virginia Health System, Charlottesville, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Geraiely, Babak" sort="Geraiely, Babak" uniqKey="Geraiely B" first="Babak" last="Geraiely">Babak Geraiely</name><affiliation><nlm:affiliation>Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32671601</idno><idno type="pmid">32671601</idno><idno type="doi">10.1007/s10557-020-07037-2</idno><idno type="pmc">PMC7360896</idno><idno type="wicri:Area/Main/Corpus">000043</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000043</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.</title><author><name sortKey="Talasaz, Azita Hajhossein" sort="Talasaz, Azita Hajhossein" uniqKey="Talasaz A" first="Azita Hajhossein" last="Talasaz">Azita Hajhossein Talasaz</name><affiliation><nlm:affiliation>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Kakavand, Hessam" sort="Kakavand, Hessam" uniqKey="Kakavand H" first="Hessam" last="Kakavand">Hessam Kakavand</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Van Tassell, Benjamin" sort="Van Tassell, Benjamin" uniqKey="Van Tassell B" first="Benjamin" last="Van Tassell">Benjamin Van Tassell</name><affiliation><nlm:affiliation>Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aghakouchakzadeh, Maryam" sort="Aghakouchakzadeh, Maryam" uniqKey="Aghakouchakzadeh M" first="Maryam" last="Aghakouchakzadeh">Maryam Aghakouchakzadeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Sadeghipour, Parham" sort="Sadeghipour, Parham" uniqKey="Sadeghipour P" first="Parham" last="Sadeghipour">Parham Sadeghipour</name><affiliation><nlm:affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Dunn, Steven" sort="Dunn, Steven" uniqKey="Dunn S" first="Steven" last="Dunn">Steven Dunn</name><affiliation><nlm:affiliation>University of Virginia Health System, Charlottesville, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Geraiely, Babak" sort="Geraiely, Babak" uniqKey="Geraiely B" first="Babak" last="Geraiely">Babak Geraiely</name><affiliation><nlm:affiliation>Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Cardiovascular drugs and therapy</title><idno type="eISSN">1573-7241</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32671601</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7241</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Cardiovascular drugs and therapy</Title><ISOAbbreviation>Cardiovasc Drugs Ther</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10557-020-07037-2</ELocationID><Abstract><AbstractText>Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Talasaz</LastName><ForeName>Azita Hajhossein</ForeName><Initials>AH</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1839-3685</Identifier><AffiliationInfo><Affiliation>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakavand</LastName><ForeName>Hessam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Tassell</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghakouchakzadeh</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghipour</LastName><ForeName>Parham</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Virginia Health System, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geraiely</LastName><ForeName>Babak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Drugs Ther</MedlineTA><NlmUniqueID>8712220</NlmUniqueID><ISSNLinking>0920-3206</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cardiovascular</Keyword><Keyword MajorTopicYN="N">Drug–drug interactions</Keyword><Keyword MajorTopicYN="N">Pharmacotherapy</Keyword><Keyword MajorTopicYN="N">SARS-Cov2</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32671601</ArticleId><ArticleId IdType="doi">10.1007/s10557-020-07037-2</ArticleId><ArticleId IdType="pii">10.1007/s10557-020-07037-2</ArticleId><ArticleId IdType="pmc">PMC7360896</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curr Probl Cardiol. 2020 Aug;45(8):100618</Citation><ArticleIdList><ArticleId IdType="pubmed">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):854-887</Citation><ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2013 Apr;88(4):315-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23541006</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81</Citation><ArticleIdList><ArticleId IdType="pubmed">30580575</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol. 2020 May;75(5):359-367</Citation><ArticleIdList><ArticleId IdType="pubmed">32282502</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2020 Jun 4;135(23):2033-2040</Citation><ArticleIdList><ArticleId IdType="pubmed">32339221</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 May - Jun;14(3):247-250</Citation><ArticleIdList><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Cardiol. 2019 Mar;35(3):326-340</Citation><ArticleIdList><ArticleId IdType="pubmed">30825953</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Jun 1;3(6):e2013136</Citation><ArticleIdList><ArticleId IdType="pubmed">32579195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2020 May 12;75(18):2372-2375</Citation><ArticleIdList><ArticleId IdType="pubmed">32199938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2019 Jun 11;73(22):2819-2828</Citation><ArticleIdList><ArticleId IdType="pubmed">30898608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kardiol Pol. 2018;76(2):229-313</Citation><ArticleIdList><ArticleId IdType="pubmed">29457615</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):e38</Citation><ArticleIdList><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209</Citation><ArticleIdList><ArticleId IdType="pubmed">30423391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2019 Nov;17(11):1989-1994</Citation><ArticleIdList><ArticleId IdType="pubmed">31410983</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Res. 2020 May 1;116(6):1097-1100</Citation><ArticleIdList><ArticleId IdType="pubmed">32227090</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2020 May 14;41(19):1798-1800</Citation><ArticleIdList><ArticleId IdType="pubmed">32186331</ArticleId></ArticleIdList></Reference><Reference><Citation>JACC Heart Fail. 2020 Jun;8(6):512-514</Citation><ArticleIdList><ArticleId IdType="pubmed">32360242</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2020 May 14;41(19):1858</Citation><ArticleIdList><ArticleId IdType="pubmed">32227120</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 Apr;46(4):586-590</Citation><ArticleIdList><ArticleId IdType="pubmed">32125455</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2020 Mar 24;75(11):1341-1350</Citation><ArticleIdList><ArticleId IdType="pubmed">32192661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2020 May;18(5):1023-1026</Citation><ArticleIdList><ArticleId IdType="pubmed">32338827</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2020 May 12;75(18):2352-2371</Citation><ArticleIdList><ArticleId IdType="pubmed">32201335</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Res. 2020 Jul;191:145-147</Citation><ArticleIdList><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2003 Feb 18;107(6):857-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12591756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Card Fail. 2020 May;26(5):370</Citation><ArticleIdList><ArticleId IdType="pubmed">32439095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2020 May;18(5):1094-1099</Citation><ArticleIdList><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d</Citation><ArticleIdList><ArticleId IdType="pubmed">23824828</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Cardiol. 2020 May;17(5):259-260</Citation><ArticleIdList><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Haematol. 2020 May;7(5):e362-e363</Citation><ArticleIdList><ArticleId IdType="pubmed">32278361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000043 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000043 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32671601
|texte= Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32671601" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |